Autoplaque vs iCAC Device

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Autoplaque

by APQ Health (formerly Cedars-Sinai Medical Center: AIM)

iCAC Device

by Bunkerhill Health

AI Verdict

Autoplaque focuses on detailed quantitative analysis of coronary plaques and luminal stenoses from CT angiography for heart attack risk prediction and treatment guidance. In contrast, the iCAC Device specializes in detecting and quantifying coronary artery calcium from routine, non-contrast CT scans for early cardiovascular disease detection. While both contribute to cardiovascular risk assessment using CT imaging, Autoplaque offers a more in-depth analysis of plaque morphology and stenosis, whereas iCAC provides opportunistic screening for calcium burden.

Choose Autoplaque if…

Choose Autoplaque if you require a detailed, quantitative analysis of coronary plaques and luminal stenoses from dedicated CT angiography images. This tool is ideal for clinicians needing precise characterization of atherosclerotic plaque and stenosis severity to guide treatment decisions and refine heart attack risk prediction. It provides automated segmentation and measurements for comprehensive cardiac assessment.

View Autoplaque →

Choose iCAC Device if…

Choose iCAC Device if you aim to opportunistically detect and quantify coronary artery calcium (CAC) from routine, non-contrast, non-gated chest CT scans. This tool is best suited for early cardiovascular disease detection and risk stratification by leveraging existing imaging data, providing Agatston scores and visual representations of CAC burden without the need for a dedicated cardiac CT.

View iCAC Device →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Autoplaque	iCAC Device
Pricing	Unknown	Contact for pricing
Deployment	Workstation-based post-processing application, runs on Windows or Mac OS.	Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform).
FDA Status	Cleared AI-estimated	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

iCAC Device

Tool B (iCAC Device) offers higher usability for routine screening due to its cloud-based Software as a Medical Device (SaMD) deployment and integration with PACS/DICOM, streamlining workflow with minimal manual intervention. Tool A (Autoplaque), while providing detailed interactive analysis with reviewable and editable segmentations, is workstation-based and requires more direct clinician engagement for post-processing, which can be less efficient for high-throughput environments.

Clinical Value

Autoplaque

Tool A (Autoplaque) provides superior clinical value by offering comprehensive quantitative analysis of coronary plaque characteristics (total, calcified, non-calcified, low-density non-calcified) and luminal stenoses from CT angiography images. This detailed information directly aids in heart attack risk prediction and treatment guidance, a broader scope than Tool B's focus solely on coronary artery calcium quantification.

Pricing & Value

Tie

Both tools have undisclosed pricing, making a direct comparison of their value propositions impossible. While initial searches suggested ambiguity regarding Autoplaque's commercialization, it is explicitly stated that APQ Health holds an exclusive license for the FDA-cleared software, confirming its availability.

Enterprise Readiness

iCAC Device

Tool B (iCAC Device) is more enterprise-ready due to its cloud-based SaMD deployment, seamless integration with PACS/DICOM systems, and explicit EHR integration capabilities via the Carebricks platform. This architecture facilitates scalable deployment and integration into existing hospital IT infrastructure, whereas Tool A's workstation-based approach may pose challenges for large-scale enterprise adoption.

Innovation

iCAC Device

Tool B (iCAC Device) demonstrates greater innovation by enabling opportunistic screening for coronary artery calcium from routine, non-contrast, non-gated chest CT scans. This approach leverages existing imaging data to identify cardiovascular risk in a broader patient population without requiring new, dedicated scans, representing a significant advancement in population health screening. While Autoplaque offers sophisticated plaque characterization, iCAC's method of data utilization is more novel in its application.

Support & Docs

Tie

Neither the provided structured facts nor the web searches yielded sufficient specific information regarding the level of support services or the availability and comprehensiveness of documentation for either tool. Therefore, a definitive comparison cannot be made.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Autoplaque	iCAC Device
Name	Autoplaque	iCAC Device
Company	Cedars-Sinai Medical Center: AIM	Bunkerhill Health
Description	Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance.	Bunkerhill Health's iCAC Device is an FDA-cleared AI algorithm that detects and quantifies coronary artery calcium from routine, non-contrast, non-gated chest CT scans, aiding in early cardiovascular disease detection.
Key Analysis Focus	AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses	Estimates presence and quantity of coronary artery calcium (CAC); Delivers exact and four-category quantitative estimates of CAC burden in Agatston units
Input Imaging	CT Angiography images	Routine, non-contrast, non-gated chest CT scans

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and iCAC Device.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What type of imaging data does each tool analyze?

Autoplaque analyzes coronary CT angiography images for quantitative plaque and stenosis assessment. iCAC Device analyzes routine, non-contrast, non-gated chest CT scans to detect and quantify coronary artery calcium.

What specific cardiovascular markers do Autoplaque and iCAC Device quantify?

Autoplaque provides AI-powered quantitative analysis of atherosclerotic plaque and measures luminal stenoses. iCAC Device estimates the presence and quantity of coronary artery calcium (CAC) in Agatston units.

What are the primary clinical applications or benefits of using each tool?

Autoplaque aids in heart attack risk prediction and treatment guidance through detailed analysis of coronary plaques and stenoses. iCAC Device assists in early cardiovascular disease detection by quantifying coronary artery calcium from existing CT scans.

Does either tool offer integration with Electronic Health Records (EHRs)?

iCAC Device integrates with EHRs via the Carebricks platform. Autoplaque's information does not specify EHR integration.

Are these tools designed for the same patient population or different diagnostic scenarios?

Autoplaque is designed for detailed analysis of coronary anatomy and pathology from CT angiography images, often used when CTA is already indicated. iCAC Device is designed for opportunistic identification and quantification of coronary artery calcium from routine, non-contrast chest CT scans, potentially for broader screening.